Navigation Links
Actavis Launches Carvedilol Tablets in the U.S.

MORRISTOWN, N.J., Sept. 5 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Carvedilol tablets in the U.S.. Distribution of the product will commence immediately.

Carvedilol tablets, the generic equivalent of GlaxoSmithKline's Coreg(R) tablets, will be available in 3.125, 6.25, 12.5 and 25 mg strength. Carvedilol tablets are indicated for the treatment of left ventricular dysfunction following myocardial infarction and for the management of essential hypertension.

Annual sales of carvedilol tablets in the U.S. were approximately US$1.7 billion for the twelve months ending June 2007 according to IMS Health data.

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 39 countries, with 11,000 employees. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market. In the U.S. alone, the company made 38 ANDA filings in 2006 and expects to file 40-45 in the year 2007 along with 18-20 new product launches. The company's U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environ

SOURCE Actavis Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Glaxo launches pills to help smokers quit in 7-12 weeks
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. Dr Reddy’s Laboratories launches Hyalosy
4. Serum Institute Launches New Tetanus-Diphtheria Vaccine
5. Scottish Health Minister Launches Organ Donor Plan
6. GlaxoSmithKline launches diabetes and cancer drugs
7. Pfizer Launches Viagra For Lung Disease In UK
8. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
9. PM Launches Healthcare Foundation For India
10. African Union Launches A Programme On Acceleration of HIV Prevention
11. Yale School of Medicine Launches Telemonitoring Of Heart Failure Symptoms
Post Your Comments:
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... ... 2015 , ... All her life, Don Peck’s mother wondered if she was a descendant of ... been. After a 25-year search for information, Don and his aunt discovered that she ... name. Turns out, it was Don’s father who was descended from not one, but ...
(Date:11/24/2015)... ... , ... Dehydration, defined as a loss of body water content, can make ... and heat stroke and death will quickly follow. A normal human body is 70 ... system and structure requires water to function properly. Kleyne, who believes that medical research ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... , the only authorized OSHA Training Institute Education Center in Northern California, is ... the holiday season’s major sales events. As the volume of sales and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Add a fresh touch to this ... and affordable way to bring long-lasting style and cheer to any space. , Holiday ... the air and keep on giving all year long. , “Holiday plants make a ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... Board of Directors has declared a special 1 percent stock ... is payable December 14, 2015, to shareholders of record December ... of additional shares of common stock. ... is a strong endorsement of our confidence in Ascendant,s growth ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of ... taking place in Chicago on Nov-29 th ... --> st  Scientific Assembly and Annual Meeting of the Radiological ... in Chicago on Nov-29 th through ... Molecular Dynamics will present its revolutionary whole body CZT digital SPECT/CT ...
(Date:11/24/2015)... November 24, 2015 --> ... Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects there. ,  ,Our 199-page ... most lucrative areas in the industry and the future ...
Breaking Medicine Technology: